TY - JOUR
T1 - Update on Allergen Immunotherapy for Allergic Rhinitis
T2 - Drops, Tablets, or Shots?
AU - Roxbury, Christopher R.
AU - Lin, Sandra Y.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2017/9
Y1 - 2017/9
N2 - Purpose of Review: Allergen immunotherapy (AIT) is the only disease-modifying treatment available for allergic rhinitis (AR). Dosing considerations, efficacy, and safety of subcutaneous (SCIT), sublingual (SLIT), and intralymphatic (ILIT) immunotherapy are discussed. Recent Findings: Patients with AR who cannot tolerate or do not wish to continue indefinite pharmacotherapy may be candidates for AIT. SCIT is the gold standard formulation but requires repeat injections over several years and may place the patient at risk for systemic allergic reactions such as anaphylaxis. SLIT has been developed as an alternative formulation by which the patient can avoid multiple injections and physician visits as it is dosed at home. SLIT has been proven to be very safe but still requires prolonged treatment, and efficacy compared to SCIT has been questioned. ILIT is currently being developed with the goal of shortening length of treatment while maintaining the efficacy and safety of SCIT and SLIT. Summary: SCIT and SLIT are current options for patients wishing to undergo AIT. Further studies are required to determine if ILIT may become an effective option for patients who do not wish to undergo long-term treatments.
AB - Purpose of Review: Allergen immunotherapy (AIT) is the only disease-modifying treatment available for allergic rhinitis (AR). Dosing considerations, efficacy, and safety of subcutaneous (SCIT), sublingual (SLIT), and intralymphatic (ILIT) immunotherapy are discussed. Recent Findings: Patients with AR who cannot tolerate or do not wish to continue indefinite pharmacotherapy may be candidates for AIT. SCIT is the gold standard formulation but requires repeat injections over several years and may place the patient at risk for systemic allergic reactions such as anaphylaxis. SLIT has been developed as an alternative formulation by which the patient can avoid multiple injections and physician visits as it is dosed at home. SLIT has been proven to be very safe but still requires prolonged treatment, and efficacy compared to SCIT has been questioned. ILIT is currently being developed with the goal of shortening length of treatment while maintaining the efficacy and safety of SCIT and SLIT. Summary: SCIT and SLIT are current options for patients wishing to undergo AIT. Further studies are required to determine if ILIT may become an effective option for patients who do not wish to undergo long-term treatments.
KW - Allergen-specific immunotherapy
KW - Allergic rhinitis
KW - Intralymphatic immunotherapy
KW - Subcutaneous immunotherapy
KW - Sublingual immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85100685947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100685947&partnerID=8YFLogxK
U2 - 10.1007/s40136-017-0159-z
DO - 10.1007/s40136-017-0159-z
M3 - Review article
AN - SCOPUS:85100685947
SN - 2167-583X
VL - 5
SP - 181
EP - 186
JO - Current Otorhinolaryngology Reports
JF - Current Otorhinolaryngology Reports
IS - 3
ER -